TAZVERIK® (tazemetostat)

Trust the oncology experts at Onco360 for TAZVERIK®

Partner with Onco360 for your epithelioid sarcoma and follicular lymphoma patients. We provide ongoing and personalized support to ensure the best clinical expertise, medication adherence, and side effect management.

TAZVERIK (tazemetostat) is a methyltransferase inhibitor indicated for the treatment of:

  • Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies.
  • Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
  • Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

TAZVERIK is available in 200 mg tablets (NDC 72607-100-00) in 240 count bottles. The recommended dosage is 800 mg taken orally twice daily with or without food.1

For full prescribing information for TAZVERIK 


Why Choose Onco360?

  • Financial assistance sourcing for qualified patients with our OncoAdvocate® team
  • Clinical programs developed by Board-Certified Oncology Pharmacists
  • #1 in patient and provider satisfaction*
  • Free delivery to patient’s doorstep

Refer Today

Limited Distribution Oncology Medications


Oncomed Dba Onco360 or
NPI# 1679618151

Limited Distribution Oncology Medications



How to Refer

1TAZVERIK prescribing information. www.tazverik.com. Accessed 6/22. Copyright Epizyme, Inc. All rights reserved.

*Third party survey data provided by MMIT for Independent Specialty Pharmacies (Oncology). Report dates Q4 2021 and Q4 2021